{
    "relation": [
        [
            "",
            "Fondaparinux 2.5 mg",
            "Placebo"
        ],
        [
            "Description",
            "Fondaparinux 2.5 milligrams (mg) administered subcutaneously (SC) once daily for 45 days",
            "Matching placebo"
        ]
    ],
    "pageTitle": "Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00443053?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989043.35/warc/CC-MAIN-20150728002309-00146-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 869374319,
    "recordOffset": 869356246,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Fondaparinux 2.5mg or placebo Intervention: Thrombosis, Venous Superficial Thrombophlebitis Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: July 2, 2010 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Fondaparinux 2.5 mg \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 1502 \u00a0 \u00a0 1500 \u00a0 COMPLETED \u00a0 \u00a0 1481 \u00a0 \u00a0 1467 \u00a0 NOT COMPLETED \u00a0 \u00a0 21 \u00a0 \u00a0 33 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 18 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 4 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}